merial to partner imu on enourmous project

Imugene has produced a vaccine
candidate for a major pig respiratory
disease using a gene provided and
owned by Merial. The commercial
vaccine candidate is currently being
trialed in Europe to determine its
effectiveness. Trial results to date have
been very promising. The disease causes
massive losses to pig producers globally
and there is currently no commercial
vaccine available. The market opportunity
for an effective vaccine is enormous given
the lack of competitors and Imugene is
working to develop this product aiming to
be first to market.
The opportunity exists to combine this
vaccine with our PRRS vaccine to create
a world dominant pig vaccine. The sales
of the combined vaccine would be
expected to be greater than the
combined sales of the individual
vaccines, as the combined disease
protection would be an enormous benefit
to pig producers.
Pig Biological Product